Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr

Pharmaceutical company Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr of 2011 compared to Rs 308 cr in a yr ago period.

Income are seen rising 8percent to Rs 2,091 cr compared to Rs 1,935 cr while the similar period.

EBITDA is likely to bounce 28percent to Rs 177 cr in July-September qtr of 2011 compared to Rs 139 cr in the similar qtr of last financial.

Operating_profit margin is anticipated to be at 8.5percent compared to 7percent yoy.

Be Sociable, Share!
Tags:

Stock Market Basics For Beginners

Who determines the IPO price?

Who determines the IPO price? The regulators don't play a role in fixing the price for IPO issues. The firm determines the value or price band in discussion along with ...…

Definitions For Interest

Definitions For Interest When you take a loan, you are expected to pay for utilizing it - that is called as a Interest. Interest is actually money charged ...…

Why Do Companies Split Their Stock? Stock Split Good?

Why Do Companies Split Their Stock? Stock Split Good? [ad name="468x15- 5 link"] A company splits their stock because administration has a theoretical ideal price range for the firm’s stock. If the market price of ...…

Share Market investment objective

Share Market investment objective your Investment objective? they invariably answer earn money with no risk. Even though all investments have an element of threat, including the possible loss of principal, ...…

SEBI’s Role in an IPO Issue

SEBI’s Role in an IPO Issue Any firm doing a public issue or a listed firm building a rights issue of value of greater than Rs 50 lakh is needed to ...…

Indian Share Tips

NSE Investment Site

Market Update

Share Guide

Designed by VMV
web
analytics